US 12,103,923 B2
Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
Maria Soraya Carrancio Anton, San Diego, CA (US); Tonia J. Buchholz, Moss Beach, CA (US); Antonia Lopez-Girona, San Diego, CA (US); Rama Krishna Narla, San Diego, CA (US); and Michael Pourdehnad, San Francisco, CA (US)
Assigned to Celgene Corporation, Summit, NJ (US)
Filed by Celgene Corporation, Summit, NJ (US)
Filed on Jun. 24, 2022, as Appl. No. 17/848,976.
Application 17/848,976 is a continuation of application No. 16/844,407, filed on Apr. 9, 2020, granted, now 11,390,617.
Claims priority of provisional application 62/833,432, filed on Apr. 12, 2019.
Prior Publication US 2022/0324855 A1, Oct. 13, 2022
Int. Cl. C07D 413/14 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 9/00 (2006.01)
CPC C07D 413/14 (2013.01) [A61P 35/00 (2018.01); C07K 16/2887 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01)] 23 Claims
 
1. A method of treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), comprising administering to a subject having the relapsed or refractory DLBCL a therapeutically effective amount of Compound 1 of the formula:

OG Complex Work Unit Chemistry
or a tautomer or pharmaceutically acceptable salt thereof, and wherein the subject has been treated with two or more prior lines of treatment, and wherein the compound is administered in an amount of about 0.1 mg to about 1.6 mg per day.